Dyspnea in a Long-Time Smoker: When the Spirometry Doesn't Explain Everything

Diagnosis: COPD, GOLD group E (more symptoms, ≥2 moderate exacerbations in the past year).

The modest bronchodilator response (90 mL, 9%) does not exclude COPD and does not make this asthma. A significant response supports reversible airflow limitation but is neither sensitive nor specific for asthma; the persistent post-bronchodilator ratio below 0.70 plus a heavy smoking history and chronic productive cough establishes persistent airflow obstruction.

Initial therapy: LAMA + LABA dual bronchodilation.

• Group E patients start on dual long-acting bronchodilators; this reduces exacerbations and improves symptoms compared with monotherapy, and avoids the pneumonia and oral candidiasis risk of inhaled corticosteroids in someone who may not benefit.
• ICS is added when there is a specific indication: blood eosinophils ≥300 cells/µL, a history of asthma features, or continued exacerbations on dual therapy. Check a CBC with differential before deciding - she has not had one.
• Do not start a single-agent LABA in COPD, and do not use the response to justify as-needed short-acting agents alone.

Pair this with the interventions that actually change outcome: smoking cessation pharmacotherapy plus counseling, influenza/COVID/pneumococcal/RSV vaccination, and pulmonary rehabilitation.

Get a DLCO and a high-resolution CT of the chest; consider referral.

Reasoning:

• COPD is a common disease, so it commonly coexists with other disease. The pattern of disproportionate dyspnea, systemic weight loss, and both obstruction and restriction on spirometry is not fully explained by emphysema alone.
• Welding fume exposure for 25 years raises the possibility of occupational lung disease - pneumoconiosis, welding-fume-related interstitial disease, or a combined emphysema/fibrosis picture. Combined pulmonary fibrosis and emphysema often shows a preserved or only mildly reduced FEV1/FVC with a low FVC and a markedly reduced DLCO.
• The unintended 12-lb weight loss also warrants evaluation for malignancy, including lung cancer screening eligibility (age 50-80, ≥20 pack-years, currently smoking or quit within 15 years) - he appears eligible and should be offered low-dose CT screening if not already done.
• A reduced DLCO in the setting of emphysema predicts oxygen desaturation with exertion and worse outcomes; it should prompt a 6-minute walk or ambulatory oximetry and consideration of home oxygen if criteria are met.

Frame it for the patient as "making sure nothing else is going on," not as contradicting the COPD diagnosis.

Ranked by expected effect:

1. Smoking cessation - the only intervention that slows the decline in FEV1. Combine varenicline or nicotine replacement with counseling; brief advice alone is the lowest-yield version of this.
2. Pulmonary rehabilitation - improves dyspnea, exercise capacity, and quality of life, and reduces readmission after exacerbation. Refer early, not as a last resort.
3. Correct inhaler technique and adherence - the most common reason a prescribed regimen fails. Observe the technique at every visit.
4. Vaccination - influenza, COVID-19, pneumococcal, and RSV (age-eligible) reduce exacerbations and hospitalizations.
5. Written action plan with rescue pack - recognizing an exacerbation early and knowing whom to call prevents admissions.
6. Assess for home oxygen if resting or exertional saturations fall to ≤88%; oxygen improves survival in chronic severe hypoxemia but not in moderate desaturation.

Note what NOT to do: no chronic oral steroids, no antibiotics for chronic colonization, and no MAC inhaler without a documented indication. Also address that his exacerbations were labeled "bronchitis" - a COPD exacerbation history should be counted and treated as such.